Hello, Guest
Login
Sign Up
 
 

Drug Markers Roundup: ANTH, BMY, PFE, ABT, ABBV

Universal penny stocks focus is on Hot Penny Stocks that trade on OTCBB and OTC markets, which are mostly referred to as “penny stocks”. These Penny Stocks could offer the greatest potential return on your short or long term investment. Sign up for our free newsletter before you miss the next alert.

 
 
Repost This

Scottsdale, AZ -- (SBWIRE) -- 01/25/2013 -- Anthera Pharmaceuticals Inc (NASDAQ:ANTH) was trading lower by 0.072 points or -10.09% to 0.645. So far, around 10.08 million shares have changed hands in this session. After opening at $0.66, the stock hit as high as $0.67. However, it traded between $0.58 and$8.42 over the last twelve months. Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing products to treat diseases associated with inflammation. The company?s development programs focus on anti-inflammatory therapeutics for cardiovascular diseases, lupus, and other serious diseases.

Has ANTH Found The Bottom and Ready To Move Up? Find Out Here

Bristol Myers Squibb Co. (NYSE:BMY) was at $36.16, showing a +0.98% increase. Around 8.57 million shares have been traded, versus an-average trading volume of 9.20 million shares. The company is now valued at around $59.69 billion. Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide.

Why Should Investors Buy BMY After The Recent Gain? Just Go Here and Find Out

Pfizer Inc. (NYSE:PFE) moved +0.20 per cent higher at $26.91 and is trading between $26.76 and $26.99 after opening the day at $26.98. Its performance over the last five days remained +1.4%, which stands at +7.22% for a month. Going back further than one month, 1-year performance after recent close was 23.8%. Pfizer Inc., a biopharmaceutical company, engages in the discovery, development, manufacture, and sale of medicines for people and animals worldwide. It primarily offers Celebrex, Chantix/Champix, Lipitor, Lyrica, Premarin, Pristiq, and Viagra pharmaceutical products in the therapeutic.

Will PFE Continue To Move Higher? Find Out Here

Abbott Laboratories (NYSE:ABT)’s shares rose today, gaining 0.03 per cent to $32.81. The stock is up around +0.17% in 2013 and +18.77% for the last 12 months. Around 4.84 million shares changed hands so far in this session compared to an-average trading volume of 11.43 million shares. Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products worldwide. It offers diagnostic systems and tests, such as immunoassay and clinical chemistry systems; assays for screening and/or diagnosis for drugs of abuse.

For How Long ABT’s Gloss will Attract Investors? Find out via this report

The share price of AbbVie Inc (NYSE:ABBV) is ranging between $36.64 and $37.74. It was +0.03% higher at $37.47. During the past 52 weeks, the stock has ranged from a high of $37.74 to a low of $37.52. So far this year, shares have gained +9.87% and 1-year performance stands around +7.23%. AbbVie Inc., a research-based pharmaceuticals company, engages in the discovery, development, manufacture, and sale of a line of pharmaceuticals and biologics worldwide. The company?s principal products are HUMIRA for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, psoriasis, juvenile idiopathic arthritis, and Crohn's disease as well as ulcerative colitis.

What was the Moving Force behind ABBV On Bullish Run? Read This Research Report on ABBV

About Universal Penny Stocks
Universalpennystocks.com is an Independent Company, our focus is on small cap stocks that trade on OTCBB and OTC markets, and are mostly referred to as “penny stocks”. These are stocks that normally trade under $5 a share and could offer the greatest potential return on your short or long term investment. You must read our Disclaimer page for more information regarding conflicts of interest and the risks involved.

We try to spot stocks in all types of market conditions. In addition, we provide emerging small cap companies with profiling and investor relations services for compensation. If you believe your company is an emerging company, with a solid product, or a company that offers our members a profitable short or long term opportunity please feel free to send us an e-mail and we’ll review the company and reply to your inquiry promptly. Please provide as much information you believe we’ll need to review your request.